PRECLINICALS


Our developments date back to 2007, when the first indications of our LDL-lowering technology were discovered. The following years have been subject to several research endeavors,  partnered with leading academic and research institutes. Throughout, we developed a strong patent lineage, with very recent patent filings to ensure an endured asset value. The high potency of our technology as well as the high selectivity for LDL-cholesterol, leaving the ‘good’ HDL cholesterol levels unaffected, were validated in many different in vivo models. These findings indicate the potential of a next-generation cholesterol lowering drug. 

ezCOL

OUR DRUG-DISCOVERY PATH


As for all drug-development efforts, ezCOL follows strict regulatory guidelines in its development to ensure that our products have the best characteristics for treating patients in a safe and effective way. From discovery, to preclinical studies up to clinical studies and subsequent market approval typically takes many years. At the moment we still invest our time and efforts in the preclinical research, in order to find the best ands safest compound for treating patients, knowing that the current marketed drugs all have some negatives and adversity with it.   

ezCOL

MAKING A DIFFERENCE FOR PATIENTS


To address the current issues with existing drug therapies, ezCOL aims to develop an LDL-cholesterol lowering drug form natural source which is positioned at statin-class like potency but without the adverse effects that come with it. Our technology is using a multitarget approach for lowering LDL-c, thereby ensuring maximal effect with minimal doses.

ezCOL